Viking Therapeutics (VKTX) Operating Leases: 2019-2025
Historic Operating Leases for Viking Therapeutics (VKTX) over the last 6 years, with Sep 2025 value amounting to $318,000.
- Viking Therapeutics' Operating Leases fell 57.88% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $318,000, marking a year-over-year decrease of 57.88%. This contributed to the annual value of $630,000 for FY2024, which is 32.69% down from last year.
- Per Viking Therapeutics' latest filing, its Operating Leases stood at $318,000 for Q3 2025, which was down 22.44% from $410,000 recorded in Q2 2025.
- Over the past 5 years, Viking Therapeutics' Operating Leases peaked at $1.5 million during Q1 2022, and registered a low of $318,000 during Q3 2025.
- Its 3-year average for Operating Leases is $769,818, with a median of $766,000 in 2024.
- Data for Viking Therapeutics' Operating Leases shows a maximum YoY slumped of 57.88% (in 2025) over the last 5 years.
- Quarterly analysis of 4 years shows Viking Therapeutics' Operating Leases stood at $1.3 million in 2022, then dropped by 25.71% to $936,000 in 2023, then tumbled by 32.69% to $630,000 in 2024, then crashed by 57.88% to $318,000 in 2025.
- Its Operating Leases stands at $318,000 for Q3 2025, versus $410,000 for Q2 2025 and $502,000 for Q1 2025.